Hilton Santa Fe Historic Plaza Hotel Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2005



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Antibody-Based Therapeutics for Cancer (B5)


Organizer(s) Louis M. Weiner and Paul Carter
February 17—22, 2005
Hilton Santa Fe Historic Plaza Hotel • Santa Fe, New Mexico USA
Abstract Deadline: Oct 18, 2004
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Dec 17, 2004

Sponsored by Genentech, Inc. and The Director's Fund

Summary of Meeting:
Monoclonal antibodies have emerged as increasingly important therapeutic vehicles for the treatment of cancer and other human diseases. Selected un-conjugated antibodies can exert clinically meaningful anti-tumor effects in important cancers such as breast cancer and lymphoma. The mechanisms underlying these exciting results remain to be elucidated, but most likely include the induction of host immune responses and the perturbation of signaling through growth factor receptors. Antibody conjugates have been used to deliver toxic principles such as radioactive particles, chemotherapy agents and catalytic toxins with increasing success in defined clinical settings. Advances in antibody engineering have permitted the systematic evaluation of structural manipulation on targeting and efficacy. Antibodies with novel specificities can be isolated with increasing ease from naive and immunized phage display libraries. Major challenges in this rapidly evolving field include the development of improved means for identifying new functional targets for antibody perturbation.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


THURSDAY, FEBRUARY 17

15:00—19:30
Registration

Promenade
18:30—19:30
Refreshments

Promenade
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom
Ronald Levy, Stanford University, USA
Antibody Therapy for Lymphoma - Progress and Prospects


FRIDAY, FEBRUARY 18

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Antibody - Fc Receptor Interactions and Manipulation
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom
E. Sally Ward, University of Texas Southwestern Medical Center, USA
FcRn as a Regulator of IgG trafficking: from Protein Engineering to Single Molecule Imaging

Raphael Clynes, Xencor, Inc., USA
Fc Receptors Link Antibody and T Cell Effector Responses in Tumor Immunity and Autoimmunity

Bassil I. Dahiyat, Xencor, USA
Fc Domain Engineering to Improve Antibody Function

* Louis M. Weiner, Georgetown University Medical Center, USA
Manipulation of Antibody Effector Function

09:20—09:40
Coffee Break

Promenade
11:00—13:00
Poster Setup

Ortiz
13:00—22:00
Poster Viewing

Ortiz
16:30—17:00
Coffee & Snacks Available

Promenade
17:00—19:15
Antibody Manipulation of Target Function
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom
* Martin J. Glennie, University of Southampton, UK
Making CD20 mAb More Effective

José Baselga, Memorial Sloan-Kettering Cancer Center, USA
Mechanisms of Action of EGFr-Inhibitory Antibodies and Small Molecules

Mark X. Sliwkowski, Genentech, Inc., USA
Therapeutic Approaches to Targeting ErbB2/HER2 in Solid Tumors

Mark D. Pegram, Stanford Cancer Institute, USA
Phase I Combined Biological Therapy of Breast Cancer Using Two Humanized Monoclonal Antibodies Directed against HER2 Proto-Oncogene and Vascular Endothelial Growth Factor (VEGF)

19:15—20:15
Social Hour

Chamisa/Ortiz
19:30—22:00
Poster Session 1

Chamisa/Ortiz

SATURDAY, FEBRUARY 19

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Novel Antibody Structures
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom
Peter J. Hudson, Aviper, Pty., Ltd., Australia
Design and Applications of Multivalent Antibody-Like Molecules

Annemarie Honegger, University of Zürich, Switzerland
Biophysical Properties of Antibody Fragments: Importance for Applications

Hilde Revets, Ablynx, Belgium
NanobodiesTM: A Novel Class of Antibody Fragments for Cancer Therapy

Carlos F. Barbas III, The Scripps Research Institute, USA
Chemical Approaches to Cancer Immunotherapy

09:20—09:40
Coffee Break

Promenade
16:30—17:00
Coffee & Snacks Available

Promenade
17:00—19:00
Radioimmunodetection and Radioimmunotherapy
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom
* Anna M. Wu, University of California, Los Angeles, USA
Tailoring Antibody Fragments for Radionuclide Delivery

Gregory P. Adams, Fox Chase Cancer Center, USA
Radioimmunotherapy of Solid Tumors with anti-HER2 Diabodies - Promise and Problems

Robert M. Sharkey, Garden State Cancer Center, USA
Pretargeting of Radionuclides for Improved Imaging and Therapy of Cancer

19:00—20:00
Social Hour

Chamisa/Ortiz

SUNDAY, FEBRUARY 20

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Advances in Antibody Engineering
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom
Jan E. Schnitzer, Proteogenomics Research Institute for Systems Medicine (PRISM), USA
Immunotargeting Endothelial Caveolae To Improve Penetration, Imaging and Therapy of Solid Tumors

Wayne A. Marasco, Dana Farber Cancer Institute, USA
Potential Use of Human Monoclonal Antibodies Against CXCR4 for Adjuvant Breast Cancer Therapy

* James D. Marks, University of California, San Francisco, USA
Tumor Cell Bindings and Internalizing Antibodies from Phage Libraries

Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Tumor Targeting Theory and Experiment

09:20—09:40
Coffee Break

Promenade
11:00—13:00
Poster Setup

Ortiz
13:00—22:00
Poster Viewing

Ortiz
16:30—17:00
Coffee & Snacks Available

Promenade
17:00—19:00
Workshop: Oral Presentations
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom
* Peter D. Senter, Seattle Genetics Inc., USA

Jan P. H. Depta, Avidex Limited, UK
Redirection of Cytotoxic T Cell Responses to MHC Class I Restricted Cancer Antigens using High Affinity T Cell Receptor-Superantigen Fusion Proteins

Veronika Rayzman, CSL Limited, Australia
Engineering and Molecular Characterisation of Chimeric Monoclonal Antibody 806 (ch806) for Targeted Immunotherapy of Tumours Expressing de2-7 EGFR or Amplified EGFR

Robin C. Humphreys, Human Genome Sciences, USA
An Agonistic, Human TRAIL Receptor 2 Monoclonal Antibody, HGS-TR2J, Stimulates the TRAIL Receptor Signaling Pathway, Actively Induces Apoptosis, Tumor Regression and Growth Inhibition in Xenograft Tumor Models

Mark S. Dennis, Denali Therapeutics, USA
Tumor Targeting and Efficacy of AB.Fab Conjugates

Pablo Umaña, Roche Innovation Center Zürich, Switzerland
Therapeutic Glycoengineered Antibodies with Higher Binding Affinity to FcgammaRIII Receptor and Increased ADCC: Comparison to Fc Polypeptide Variants and New Mechanistic Findings

19:00—20:00
Social Hour

Chamisa/Ortiz
19:30—22:00
Poster Session 2

Chamisa/Ortiz

MONDAY, FEBRUARY 21

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Antibodies as Effector Molecules
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom
* Paul Carter, Genentech, Inc., USA
Redesigning Antibodies for Drug Conjugation for Cancer Therapy

Sherie L. Morrison, University of California, Los Angeles, USA
Antibody Fusion Proteins for Cancer Immunotherapy

* Richard H.J. Begent, University College London, UK
Antibody-Directed Enzyme Prodrug Therapy

Dario Neri, ETH Zürich, Switzerland
Antibody-Based Targeting of Tumor Neo-Vasculature

09:20—09:40
Coffee Break

Promenade
16:30—17:00
Coffee & Snacks Available

Promenade
17:00—19:00
Clinical Updates and New Directions
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
Jan van de Winkel, Genmab, Netherlands
Novel Human Antibodies Targeting CD20

* George J. Weiner, University of Iowa, USA
Monoclonal Antibody Therapy and NK Activation

Soldano Ferrone, University of Pittsburgh, USA
Structural Basis of Human High Molecular Weight-Melanoma Associated Antigen Mimicry by Mouse Anti-Idiotypic Monoclonal Antibody MK2-23

19:00—20:00
Social Hour

Promenade
20:00—23:00
Entertainment

Mesa Ballroom

TUESDAY, FEBRUARY 22

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13-CA112789-01




We gratefully acknowledge additional support for this conference from:

Genentech, Inc. Novartis Institutes for BioMedical Research
Seattle Genetics, Inc.
Bayer USA Foundation

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Genentech, Inc.


Seattle Genetics, Inc.


Xencor, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676